254 related articles for article (PubMed ID: 23985681)
81. Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B.
Roelofs PA; Goh CY; Chua BH; Jarvis MC; Stewart TA; McCann JL; McDougle RM; Carpenter MA; Martens JW; Span PN; Kappei D; Harris RS
Elife; 2020 Sep; 9():. PubMed ID: 32985974
[TBL] [Abstract][Full Text] [Related]
82. Clearing of Foreign Episomal DNA from Human Cells by CRISPRa-Mediated Activation of Cytidine Deaminases.
Brezgin S; Kostyusheva A; Ponomareva N; Volia V; Goptar I; Nikiforova A; Shilovskiy I; Smirnov V; Kostyushev D; Chulanov V
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962129
[TBL] [Abstract][Full Text] [Related]
83. The surprising activities of APOBEC3B and 5-fluorouracil.
Walton EL
Biomed J; 2015; 38(2):97-100. PubMed ID: 25872558
[TBL] [Abstract][Full Text] [Related]
84. Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons.
Jost S; Turelli P; Mangeat B; Protzer U; Trono D
J Virol; 2007 Oct; 81(19):10588-96. PubMed ID: 17652382
[TBL] [Abstract][Full Text] [Related]
85. APOBEC3B expression in drug resistant MCF-7 breast cancer cell lines.
Onguru O; Yalcin S; Rosemblit C; Zhang PJ; Kilic S; Gunduz U
Biomed Pharmacother; 2016 Apr; 79():87-92. PubMed ID: 27044816
[TBL] [Abstract][Full Text] [Related]
86. Pan-cancer transcriptomic analysis dissects immune and proliferative functions of APOBEC3 cytidine deaminases.
Ng JCF; Quist J; Grigoriadis A; Malim MH; Fraternali F
Nucleic Acids Res; 2019 Feb; 47(3):1178-1194. PubMed ID: 30624727
[TBL] [Abstract][Full Text] [Related]
87. No evidence of an association between the APOBEC3B deletion polymorphism and susceptibility to HIV infection and AIDS in Japanese and Indian populations.
Itaya S; Nakajima T; Kaur G; Terunuma H; Ohtani H; Mehra N; Kimura A
J Infect Dis; 2010 Sep; 202(5):815-6; author reply 816-7. PubMed ID: 20684727
[No Abstract] [Full Text] [Related]
88. APOBEC3A/B deletion polymorphism and cancer risk.
Gansmo LB; Romundstad P; Hveem K; Vatten L; Nik-Zainal S; Lønning PE; Knappskog S
Carcinogenesis; 2018 Feb; 39(2):118-124. PubMed ID: 29140415
[TBL] [Abstract][Full Text] [Related]
89. Targeting APOBECs in cancer: It's about timing.
Hata AN; Larijani M
Cancer Cell; 2024 Apr; 42(4):497-501. PubMed ID: 38593778
[TBL] [Abstract][Full Text] [Related]
90.
Sasaki H; Suzuki A; Tatematsu T; Shitara M; Hikosaka Y; Okuda K; Moriyama S; Yano M; Fujii Y
Biomed Rep; 2014 May; 2(3):392-395. PubMed ID: 24748981
[TBL] [Abstract][Full Text] [Related]
91. Genomics: Mutator catalogues.
Alderton GK
Nat Rev Cancer; 2013 Oct; 13(10):681. PubMed ID: 24060860
[No Abstract] [Full Text] [Related]
92. Computational drug discovery of an inhibitor of APOBEC3B as a treatment for epithelial cancers.
Caputa DA; Blankenship QP; Smith ZD; Huebner MM; Vetter ZA; Parks RW; Armendariz Lobera S; Leddin EM; Taylor CA; Parish CA; Miller BR
J Biomol Struct Dyn; 2023 Dec; ():1-14. PubMed ID: 38109103
[TBL] [Abstract][Full Text] [Related]
93. APOBEC3A drives STING-dependent metastasis.
Bakhoum SF
Nat Cancer; 2021 Dec; 2(12):1293-1295. PubMed ID: 35121905
[No Abstract] [Full Text] [Related]
94. A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3'UTR enhances chromosomal DNA damage.
Caval V; Suspène R; Shapira M; Vartanian JP; Wain-Hobson S
Nat Commun; 2014 Oct; 5():5129. PubMed ID: 25298230
[TBL] [Abstract][Full Text] [Related]
95. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer.
Nik-Zainal S; Wedge DC; Alexandrov LB; Petljak M; Butler AP; Bolli N; Davies HR; Knappskog S; Martin S; Papaemmanuil E; Ramakrishna M; Shlien A; Simonic I; Xue Y; Tyler-Smith C; Campbell PJ; Stratton MR
Nat Genet; 2014 May; 46(5):487-91. PubMed ID: 24728294
[TBL] [Abstract][Full Text] [Related]
96. APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity.
Swanton C; McGranahan N; Starrett GJ; Harris RS
Cancer Discov; 2015 Jul; 5(7):704-12. PubMed ID: 26091828
[TBL] [Abstract][Full Text] [Related]
97. APOBEC3B: pathological consequences of an innate immune DNA mutator.
Burns MB; Leonard B; Harris RS
Biomed J; 2015; 38(2):102-10. PubMed ID: 25566802
[TBL] [Abstract][Full Text] [Related]
98. FHIT loss-induced DNA damage creates optimal APOBEC substrates: Insights into APOBEC-mediated mutagenesis.
Waters CE; Saldivar JC; Amin ZA; Schrock MS; Huebner K
Oncotarget; 2015 Feb; 6(5):3409-19. PubMed ID: 25401976
[TBL] [Abstract][Full Text] [Related]
99. AID and APOBEC deaminases: balancing DNA damage in epigenetics and immunity.
Franchini DM; Petersen-Mahrt SK
Epigenomics; 2014; 6(4):427-43. PubMed ID: 25333851
[TBL] [Abstract][Full Text] [Related]
100.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
